We found in this study a correlation between high expression of MLKL, TRAF2, and RIPK1 and the most malignant SCLC S-III subtype, suggesting that these proteins may represent good targets for treating SCLC. The gene discussed is TRAF2; the disease is small cell lung carcinoma.